Virus isolation and neutralisation of SARS-CoV-2 variants BA.2.86 and EG.5.1
Lancet Infect Dis
.
2023 Dec;23(12):e509-e510.
doi: 10.1016/S1473-3099(23)00682-5.
Epub 2023 Nov 7.
Authors
Ria Lassaunière
1
,
Charlotta Polacek
2
,
Magdalena Utko
3
,
Karina M Sørensen
3
,
Sharmin Baig
4
,
Kirsten Ellegaard
4
,
Leandro A Escobar-Herrera
4
,
Anders Fomsgaard
2
,
Katja Spiess
2
,
Vithiagaran Gunalan
2
,
Marc Bennedbæk
2
,
Jannik Fonager
2
,
Olivier Schwartz
5
,
Delphine Planas
5
,
Etienne Simon-Lorière
6
,
Uffe V Schneider
7
,
Raphael N Sieber
4
,
Marc Stegger
8
,
Lene Nielsen
9
,
Morten Hoppe
9
,
Tyra G Krause
10
,
Henrik Ullum
11
,
Pikka Jokelainen
12
,
Morten Rasmussen
2
Affiliations
1
Virus Research and Development Laboratory, Virus & Microbiological Special Diagnostics, Copenhagen 2300, Denmark. Electronic address: mlas@ssi.dk.
2
Virus Research and Development Laboratory, Virus & Microbiological Special Diagnostics, Copenhagen 2300, Denmark.
3
Danish National Biobank, Copenhagen 2300, Denmark.
4
Sequencing and Bioinformatics, Bacteria, Parasites & Fungi, Copenhagen 2300, Denmark.
5
Virus & Immunity Unit, Department of Virology, Institut Pasteur, Paris, France; CNRS UMR 3569, Paris, France; Vaccine Research Institute, Créteil, France.
6
G5 Evolutionary Genomics of RNA Viruses, Institut Pasteur, Paris, France.
7
Virus Preparedness, Virus & Microbiological Special Diagnostics, Copenhagen 2300, Denmark.
8
Sequencing and Bioinformatics, Bacteria, Parasites & Fungi, Copenhagen 2300, Denmark; Antimicrobial Resistance and Infectious Diseases Laboratory, Harry Butler Institute, Murdoch University, Perth, WA, Australia.
9
Department of Clinical Microbiology, Copenhagen University Hospital, Herlev and Gentofte, Denmark.
10
Epidemiological Infectious Disease Preparedness, Copenhagen 2300, Denmark.
11
Statens Serum Institut, Copenhagen 2300, Denmark.
12
Infectious Disease Preparedness, Copenhagen 2300, Denmark.
PMID:
37949089
DOI:
10.1016/S1473-3099(23)00682-5
No abstract available
Publication types
Letter
MeSH terms
Antibodies, Neutralizing
Antibodies, Viral
COVID-19*
Humans
SARS-CoV-2* / genetics
Substances
Antibodies, Viral
Antibodies, Neutralizing
Supplementary concepts
SARS-CoV-2 variants